引用本文
  • 王健民.原代小鼠骨骼肌细胞和C2C12细胞转人凝血因子Ⅸ基因后高效表达及分泌功能[J].第二军医大学学报,1999,20(9):    [点击复制]
  • 王健民.Secreting human factor Ⅸ with high efficiency by murine primary and C2C12 muscle cells carrying human factor Ⅸ gene[J].Acad J Sec Mil Med Univ,1999,20(9):   [点击复制]
【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 1133次   下载 273  
原代小鼠骨骼肌细胞和C2C12细胞转人凝血因子Ⅸ基因后高效表达及分泌功能
王健民
0
(第二军医大学长海医院血液内科 美国密歇根大学人类遗传系)
摘要:
目的:研究骨骼肌细胞作为基因治疗靶细胞,其合成、加工和分泌外源性蛋白质的功能。方法:应用骨骼肌细胞特异性和非特异性表达载体(pdLMe4bAhⅨm和LⅨSN)转染联合免疫缺陷(SCID)小鼠原代成肌细胞(SCID-MB)和C2C12成肌细胞系,观察这两种细胞在合成、加工和分泌人凝血因子Ⅸ(FⅨ)蛋白质方面的异同。结果:在SCID-MB中,pdLMe4bAhⅨm可表达的FⅨ 达2 000ng.10-6.(24 h)-1,凝血活性达95%?103%。比较细胞内和培养上清液中的FⅨ蛋白及细胞内FⅨ mRNA丰度变化表明,C2C12细胞分泌FⅨ的功能不如SCID-MB,而合成、加工FⅨ的能力与SCID-MB相似。结论:原代小鼠骨骼肌细胞可高效表达、加工和分泌外源性基因产物;在以骨骼肌细胞作为靶细胞进行基因治疗研究时,应尽量应用原代细胞。本研究为临床应用骨骼肌细胞作为基因治疗靶细胞奠定了实验基础。
关键词:  骨骼肌成肌细胞  凝血因子Ⅸ  基因治疗
DOI:
基金项目:
Secreting human factor Ⅸ with high efficiency by murine primary and C2C12 muscle cells carrying human factor Ⅸ gene
王健民
()
Abstract:
Objective:To study systematically the role of skeletal muscle cells in synthesizing, processing and secreting recombinant proteins in vitro. Methods: Primary murine myoblasts from SCID mice (SCID-MB) and C2C12, a mouse myoblast cell line, were transfected with muscle specific (pdLMe4bAhⅨm) or non-specific (LⅨSN) vectors encoding human factor Ⅸ (FⅨ). The capacities of the transgenic cells in producing recombinant FⅨ were compared in the levels of intracellular and secreted FⅨ protein as well as FⅨ mRNA in primary muscle cells and C2C12 cells. Results: Both primary muscle cells and C2C12 cells can efficiently translate and process FⅨ protein. Myotubes derived from the SCID-MB produced-2000 ng FⅨ.(106 cells)-1.(24 h)-1 in culture with specific activity of 95%?103%. C2C12 cells can synthesize and process recombinant FⅨ as efficiently as primary muscle cells, but their secretion ability is less efficient in comparison with primary cells. Conclusion: The primary cells should be used in gene therapy related research projects and care should be taken while explaining the results derived from established cell lines.
Key words:  skeletal myoblasts  coagulation factor Ⅸ  gene therapy